Literature DB >> 21745013

Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management.

Sigurdur Y Kristinsson1, Alex R Minter, Neha Korde, Esther Tan, Ola Landgren.   

Abstract

The manifestations of bone involvement in patients with multiple myeloma (MM) can have devastating clinical effects and increase mortality. Recent studies demonstrate that patients with the precursor conditions smoldering MM (SMM) and monoclonal gammopathy of undetermined significance (MGUS) show evidence of bone disease and increased risk of fractures. The understanding of the pathogenesis of bone disease in MM has expanded in recent years. The traditional skeletal survey will probably be replaced by newer and more sensitive imaging techniques, which may have a prognostic impact and change our definition of MGUS and SMM. Bisphosphonates are recommended to prevent skeletal events in patients with MM, and have also been studied in SMM and MGUS. This article summarizes the current knowledge of bone disease in plasma cell disorders, and discusses the current standard and future role of novel imaging techniques, as well as the evidence and current guidelines for bisphosphonates in MM, SMM and MGUS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21745013      PMCID: PMC3199399          DOI: 10.1586/erm.11.44

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  99 in total

1.  Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies.

Authors:  Thacharot Boonyapakorn; Ingrid Schirmer; Peter A Reichart; Isrid Sturm; Gero Massenkeil
Journal:  Oral Oncol       Date:  2008-02-20       Impact factor: 5.337

2.  Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss.

Authors:  James R Berenson; Ori Yellin; Ralph V Boccia; Marshall Flam; Siu-Fun Wong; Olcay Batuman; Mehdi M Moezi; Donald Woytowitz; Herbert Duvivier; Youram Nassir; Regina A Swift
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

3.  Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma.

Authors:  C Jakob; J Sterz; P Liebisch; M Mieth; J Rademacher; A Goerke; U Heider; C Fleissner; M Kaiser; I von Metzler; C Müller; O Sezer
Journal:  Leukemia       Date:  2008-06-26       Impact factor: 11.528

4.  A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma.

Authors:  Pellegrino Musto; Maria Teresa Petrucci; Sara Bringhen; Tommasina Guglielmelli; Tommaso Caravita; Velia Bongarzoni; Alessandro Andriani; Giovanni D'Arena; Enrico Balleari; Giuseppe Pietrantuono; Mario Boccadoro; Antonio Palumbo
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

5.  Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma.

Authors:  Martin Kaiser; Maren Mieth; Peter Liebisch; Romy Oberländer; Jessica Rademacher; Christian Jakob; Lorenz Kleeberg; Claudia Fleissner; Edgar Braendle; Malte Peters; David Stover; Orhan Sezer; Ulrike Heider
Journal:  Eur J Haematol       Date:  2008-03-10       Impact factor: 2.997

6.  The effects of alendronate treatment in osteoporotic patients affected by monoclonal gammopathy of undetermined significance.

Authors:  Jessica Pepe; Maria Teresa Petrucci; Maria Lucia Mascia; Sara Piemonte; Valeria Fassino; Elisabetta Romagnoli; Salvatore Minisola
Journal:  Calcif Tissue Int       Date:  2008-06       Impact factor: 4.333

Review 7.  Pathogenesis of myeloma bone disease.

Authors:  G D Roodman
Journal:  Leukemia       Date:  2008-11-27       Impact factor: 11.528

8.  Natural history of osteonecrosis of the jaw in patients with multiple myeloma.

Authors:  Ashraf Badros; Evangelos Terpos; Eirini Katodritou; Olga Goloubeva; Efstathios Kastritis; Evgenia Verrou; Kostas Zervas; Maria R Baer; Timothy Meiller; Meletios A Dimopoulos
Journal:  J Clin Oncol       Date:  2008-11-17       Impact factor: 44.544

9.  Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma.

Authors:  Sigurdur Y Kristinsson; Thomas R Fears; Gloria Gridley; Ingemar Turesson; Ulf-Henrik Mellqvist; Magnus Björkholm; Ola Landgren
Journal:  Blood       Date:  2008-06-17       Impact factor: 22.113

10.  Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI).

Authors:  T G Gleeson; J Moriarty; C P Shortt; J P Gleeson; P Fitzpatrick; B Byrne; J McHugh; M O'Connell; P O'Gorman; S J Eustace
Journal:  Skeletal Radiol       Date:  2008-11-14       Impact factor: 2.199

View more
  13 in total

1.  CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease.

Authors:  Sarah K Johnson; James P Stewart; Rakesh Bam; Pingping Qu; Bart Barlogie; Frits van Rhee; John D Shaughnessy; Joshua Epstein; Shmuel Yaccoby
Journal:  Blood       Date:  2014-07-24       Impact factor: 22.113

2.  Decreased ferroportin promotes myeloma cell growth and osteoclast differentiation.

Authors:  Zhimin Gu; He Wang; Jiliang Xia; Ye Yang; Zhendong Jin; Hongwei Xu; Jumei Shi; Ivana De Domenico; Guido Tricot; Fenghuang Zhan
Journal:  Cancer Res       Date:  2015-04-08       Impact factor: 12.701

3.  Bone disease in monoclonal gammopathy of undetermined significance: results from a screened population-based study.

Authors:  Sigrun Thorsteinsdottir; Sigrun H Lund; Ebba K Lindqvist; Marianna Thordardottir; Gunnar Sigurdsson; Rene Costello; Debra Burton; Hlif Steingrimsdottir; Vilmundur Gudnason; Gudny Eiriksdottir; Kristin Siggeirsdottir; Tamara B Harris; Ola Landgren; Sigurdur Y Kristinsson
Journal:  Blood Adv       Date:  2017-12-21

Review 4.  An Evidence-Based Approach to Myeloma Bone Disease.

Authors:  Nicholas Bingham; Antonia Reale; Andrew Spencer
Journal:  Curr Hematol Malig Rep       Date:  2017-04       Impact factor: 3.952

5.  Prognostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at diagnosis in untreated multiple myeloma patients: a systematic review and meta-analysis.

Authors:  Qian Li; Linhui Hu; Alice Charwudzi; Weiwei Zhu; Ye Meng; Zhimin Zhai
Journal:  Clin Exp Med       Date:  2022-01-09       Impact factor: 3.984

6.  Prognostic significance of 18F-sodium fluoride in newly diagnosed multiple myeloma patients.

Authors:  Mahdi Zirakchian Zadeh; Siavash Mehdizadeh Seraj; Brian Østergaard; Stephanie Mimms; William Y Raynor; Mahmoud Aly; Austin J Borja; Leila S Arani; Oke Gerke; Thomas J Werner; Hongming Zhuang; Mona-Elisabeth Revheim; Niels Abildgaard; Poul Flemming Høilund-Carlsen; Abass Alavi
Journal:  Am J Nucl Med Mol Imaging       Date:  2020-08-25

7.  2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induces peripheral blood abnormalities and plasma cell neoplasms resembling multiple myeloma in mice.

Authors:  Lei Wang; Munish Kumar; Qipan Deng; Xu Wang; Ming Liu; Zhaojian Gong; Shanshan Zhang; Xiaodong Ma; Zijun Y Xu-Monette; Min Xiao; Qing Yi; Ken H Young; Kenneth S Ramos; Yong Li
Journal:  Cancer Lett       Date:  2018-10-19       Impact factor: 8.679

Review 8.  New Approaches to Molecular Imaging of Multiple Myeloma.

Authors:  Ravi Vij; Kathryn J Fowler; Monica Shokeen
Journal:  J Nucl Med       Date:  2015-11-05       Impact factor: 10.057

9.  Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment.

Authors:  X Leleu; C Kyriakou; I Vande Broek; P Murphy; P Bacon; P Lewis; H Gilet; B Arnould; M T Petrucci
Journal:  Blood Cancer J       Date:  2017-03-17       Impact factor: 11.037

10.  Very late antigen-4 (α(4)β(1) Integrin) targeted PET imaging of multiple myeloma.

Authors:  Deepti Soodgupta; Michelle A Hurchla; Majiong Jiang; Alexander Zheleznyak; Katherine N Weilbaecher; Carolyn J Anderson; Michael H Tomasson; Monica Shokeen
Journal:  PLoS One       Date:  2013-02-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.